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AbstractThe originally-proposed PRECISE-DAPT score is a 5-item risk score supporting decision-making for dual antiplatelet
therapy1 duration after PCI. It is unknown if a simplified version of the score based on 4 factors (age, hemoglobin, creatinine
clearance, prior bleeding), and lacking white-blood cell count, retains potential to guide DAPT duration. The 4-item PRECISE-
DAPT was used to categorize 10,081 patients who were randomized to short (3-6 months) or long (12-24 months) DAPT
regimen according to high (HBR defined by PRECISE-DAPT ≥25 points) or non-high bleeding risk (PRECISE-DAPTb25) status.
Long treatment duration was associated with higher bleeding rates in HBR (ARD +2.22% [95% CI +0.53 to +3.90]) but not in
non-HBR patients (ARD +0.25% [−0.14 to +0.64]; pint = 0.026), and associated with lower ischemic risks in non-HBR (ARD
−1.44% [95% CI −2.56 to −0.31]), but not in HBR patients (ARD +1.16% [−1.91 to +4.22]; pint = 0.11). Only non-HBR
patients experienced lower net clinical adverse events (NACE) with longer DAPT (pint = 0.043). A 4-item simplified version of
the PRECISE-DAPT score retains the potential to categorize patients who benefit from prolonged DAPT without concomitant
bleeding liability from those who do not. (Am Heart J 2020;223:44-47.)Introduction
The PRECISE-DAPT score is a 5-item bleeding risk
prediction tool developed for patients treated with dual
antiplatelet therapy.1,2 By stratifying patients according
to the baseline bleeding risk, PRECISE-DAPT has shown
potential to inform decision-making for DAPT duration
after percutaneous coronary intervention1-3 and it has
been endorsed by international guidelines and routine
clinical practice worldwide.4 A simplified version of this
score lacking white blood cells count (WBC) and
therefore based on 4 factors (i.e. age, hemoglobin,
creatinine clearance, prior bleeding requiring medical
attention) has been previously generated, showing only
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item iteration in both the generation and validation
datasets.2 The aim of the current analysis was to test
whether this simplified version of the score helps
categorizing patients at high bleeding risk (HBR) who
should receive shortened DAPT after PCI.Methods
We sought to assess the role of a 4-item PRECISE-DAPT
score to guide decision-making on DAPT duration across
10,081 patients who were randomly allocated to short (3
or 6 months) or long (12 or up to 24 months) DAPT
duration within the PRECISE DAPT pooled dataset.
Details regarding the individual study inclusion/exclusion
criteria, procedural characteristics, endpoints definitions
event adjudication and regulatory approval were previ-
ously reported.2 The 4-item simplified PRECISE-DAPT
was obtained by excluding white blood cell count (WBC)
at baseline, and by re-weighing the other 4 score
components within the multivariable model as previously
described.2 Score discrimination and calibration were
previously evaluated in both the generation cohort, and
in two, independent, validation cohorts.2
In the current analysis, we assessed the impact of the
randomly allocated short and long DAPT durations on
bleeding (i.e. TIMI major or minor definition), ischemic
events (i.e. composite of myocardial infarction, stent
thrombosis, stroke or target vessel revascularization), and
net adverse clinical events (NACE, i.e. the combination of
aforementioned ischemic and bleeding events) across the
Figure 1
Impact of dual antiplatelet therapy duration across the 4-item PRECISE-DAPT score quartiles. Absolute risk difference (ARD)
for long (12-24 months) as compared to short (3-6 months) DAPT duration across the 4-item PRECISE-DAPT score quartiles for bleeding (TIMI
major/minor definition), ischemic (composite of myocardial infarction, definite stent thrombosis, stroke or target vessel revascularization) and net
adverse clinical events (NACE) (composite of ischemic and bleeding endpoints) are presented. Bars plotted on the upper side of the zero line
represent benefit of long versus short DAPT duration, whereas bars plotted on the lower side of the zero line represent harm from long versus short
DAPT duration.
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Volume 223, Number 0simplified 4-item PRECISE-DAPT score quartiles (i.e. very-
low ≤7 points, low 8 to 15 points, moderate 16 to 24
points, high ≥25 points). Interaction between high
(highest quartile) versus non-high (lowest three quartiles)
4-item PRECISE DAPT score and DAPT duration was
evaluated by assessing heterogeneity for absolute risk
differences. All analysis were performed with R version
3.6 (R Foundation, Vienna, Austria), and a P b.05 was
considered for statistical significance. No extramural
funding was used to support this work.
Results
The median simplified 4-item PRECISE-DAPT score was
14.8 points (IQR: 7−24) and a total of 3496 patients (23.4%)
were considered at HBR (ie, score ≥25 points). Longer
treatment duration was associated with a significant excess
of bleeding events exclusively in HBR patients (ARD +2.22%
[95% CI +0.53 to +3.90]; number needed to treat [NNT]: 45)
but not in those without HBR profile (i.e., very low, low or
moderate risk: ARD +0.25% [−0.14 to +0.64]; pint = 0.026)(
Figure 1). This remained consistent when only eventsoccurring during the first year after PCI were accounted for
(pint = 0.042). Concurrently, longer DAPT duration was
associated with lower rates of the composite ischemic
endpoint of myocardial infarction, definite stent thrombosis,
stroke, or target vessel revascularization in non-HBR patients
(ARD −1.44% [95% CI −2.56 to −0.31]; NNT: 69), but not in
those at HBR (ARD +1.16% [−1.91 to +4.22]; pint = 0.11)(
Figure 1).Whenboth ischemic andbleeding endpointswere
simultaneously considered in a NACE endpoint, non-HBR
patients benefitted from longerDAPTduration (ARD−1.29%
[95% CI −2.46 to −0.13]; NNT: 77), while HBR patients did
not (ARD +2.36% [95% CI −0.99 to 5.69]; pint = 0.043) (
Figure 1).
Discussion
In the current analysis, which was carried out in a
pooled dataset of 5 randomized studies and including
more than 10,000 patients, we show for the first time that
a simplified 4-item PRECISE-DAPT score (i.e. excluding
WBC) may prove useful to support clinical decision-
making for DAPT duration. At a cut-off of 25 points
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Month Year(consistent with that provided by the 5-item score), the
simplified PRECISE-DAPT score was able to identify
patients at higher bleeding risk who do not apparently
derive benefits, and may actually be harmed, by longer
treatment duration. On the other hand, non-HBR patients
derived ischemic benefit from longer DAPT duration
without being exposed to significant bleeding risk.
Hence, the simplified 4-item PRECISE-DAPT score retains
the ability to inform DAPT duration decision-making.
Personalized DAPT treatment after stenting has been
extensively investigated in recent years,4-7 and several
clinical and technical characteristics,8-10 as well as clinical
risk scores,11 were shown to support clinical decision
making.4, 6 The PRECISE-DAPT score implements bleed-
ing risk status at the time of PCI and it was previously
shown to provide decision-making potentials for short
versus long-term DAPT duration even in patients at
concomitantly very high ischemic risk such as those with
ACS undergoing complex PCI.1, 2 Yet, despite this tool
has been widely endorsed from international societies
and guidelines, and widely implemented in real world
practice, several barriers for the routine application of
risk scores still exist.12
On this matter, the simplified 4-item iteration of the
PRECISE-DAPT score presented in the current analysis
may prove useful for at least three reasons: first,
accounting on 4, rather than 5, factors, allows for faster
score computation in clinical practice; second, WBC
levels change over time during hospital stay, especially in
acute coronary syndrome patients, and may create
ambiguity in patient categorization.13 In this case, a
second evaluation with this simplified tool may facilitate a
more unbiased risk assessment. Third, this version of the
score may facilitate prospective or retrospective compu-
tation of the PRECISE-DAPT score in various datasets in
which WBC values is not available.Conclusions
A simplified 4-item PRECISE-DAPT score excluding
WBC maintains the capability to categorize patients who
benefit or not from prolonged DAPT, and may offer an
alternative solution for risk stratification and decision
making purposes in settings where WBC is not available.
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